1. Home
  2. GETY vs IFRX Comparison

GETY vs IFRX Comparison

Compare GETY & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Getty Images Holdings Inc.

GETY

Getty Images Holdings Inc.

N/A

Current Price

$0.41

Market Cap

253.5M

Sector

Industrials

ML Signal

N/A

Logo InflaRx N.V.

IFRX

InflaRx N.V.

N/A

Current Price

$1.70

Market Cap

303.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GETY
IFRX
Founded
1995
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
253.5M
303.4M
IPO Year
2022
2017

Fundamental Metrics

Financial Performance
Metric
GETY
IFRX
Price
$0.41
$1.70
Analyst Decision
Hold
Strong Buy
Analyst Count
3
4
Target Price
$3.78
$6.25
AVG Volume (30 Days)
5.3M
1.3M
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$926,244,000.00
N/A
Revenue This Year
$0.37
N/A
Revenue Next Year
$1.47
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.82
N/A
52 Week Low
$0.42
$0.74
52 Week High
$3.21
$2.95

Technical Indicators

Market Signals
Indicator
GETY
IFRX
Relative Strength Index (RSI) 30.59 35.86
Support Level N/A $0.87
Resistance Level $0.93 $1.94
Average True Range (ATR) 0.06 0.14
MACD -0.03 -0.04
Stochastic Oscillator 8.00 4.26

Price Performance

Historical Comparison
GETY
IFRX

About GETY Getty Images Holdings Inc.

Getty Images Holdings Inc. is a visual content creator and marketplace that offers a full range of content solutions. Through its Getty Images, Stock, and Unsplash brands, websites, and APIs, it serves customers around the world by allowing them to discover, purchase, and share visual content from photographers, illustrators, image partners, and videographers. The company generates a majority of its revenue through subscriptions, offering various subscription products on the Getty Images, iStock, and Unsplash websites. It operates and manages one operating segment, which is the business of developing and commercializing visual content. Geographically, the company generates maximum revenue from the Americas, followed by Europe, the Middle East and Africa, and the Asia-Pacific region.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: